These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 10517730)

  • 21. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
    Demers C
    Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
    Fox KA
    Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
    Fox KA
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):67-74. PubMed ID: 11449345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
    Montalescot G; Philippe F; Ankri A; Vicaut E; Bearez E; Poulard JE; Carrie D; Flammang D; Dutoit A; Carayon A; Jardel C; Chevrot M; Bastard JP; Bigonzi F; Thomas D
    Circulation; 1998 Jul; 98(4):294-9. PubMed ID: 9711933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
    Ibbotson T; Goa KL
    Drugs; 2002; 62(9):1407-30. PubMed ID: 12076195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
    Antman EM; McCabe CH; Braunwald E
    Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.
    Sabatine MS; McCabe CH; Morrow DA; Giugliano RP; de Lemos JA; Cohen M; Antman EM; Braunwald E
    Am Heart J; 2002 Jun; 143(6):966-70. PubMed ID: 12075250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
    Montalescot G; Collet JP; Lison L; Choussat R; Ankri A; Vicaut E; Perlemuter K; Philippe F; Drobinski G; Thomas D
    J Am Coll Cardiol; 2000 Jul; 36(1):110-4. PubMed ID: 10898421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
    Bozovich GE; Gurfinkel EP; Antman EM; McCabe CH; Mautner B
    Am Heart J; 2000 Oct; 140(4):637-42. PubMed ID: 11011339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
    Monrad ES
    Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.